RBC Capital says that as expected, Verona Pharma’s (VRNA) Ohtuvayre was approved for maintenance treatment of chronic obstructive pulmonary disease. The firm expects Regeneron’s (REGN) Dupixent should be able to “easily co-exist” with Ohtuvayre and notes a few label surprises likely favor Regeneron. The Ohtuvayre label contains a warning about suicidality/psychiatric adverse events, which could give some doctors pause in some patients, the analyst tells investors in a research note. RBC remains a buyer of Regeneron based on its optimism around Dupixent’s near- and long-term growth across indications. It has an Outperform rating on the shares with a $1,229 price target.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on REGN:
- Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine
- Intellia reports proof-of-concept data for redosing CRISPR-based therapy
- Regeneron price target raised to $1,170 from $1,060 at Argus
- Regeneron (NASDAQ:REGN): Is This Stock-Split Contender a Strong Buy?
- Regeneron presents follow-up data from pivotal Phase 1/2 LINKER-MM1 trial